Neoadjuvant rh-endostatin, docetaxel and epirubicin for breast cancer: efficacy and safety in a prospective, randomized, phase II study

BACKGROUND: Recombinant human endostatin (rh-endostatin) is a novel antiangiogenesis drug developed in China. Previous experiments have shown that rh-endostatin can inhibit the proliferation and migration of endothelial cells and some types of tumor cells. In this study, we evaluated the efficacy an...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Chen, Jianghao, Yao, Qing, Li, Dong, Zhang, Juliang, Wang, Ting, Yu, Ming, Zhou, Xiaodong, Huan, Yi, Wang, Jing, Wang, Ling
Format: Artigo
Sprache:Inglês
Veröffentlicht: BioMed Central 2013
Schlagworte:
Research Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3664086/
https://ncbi.nlm.nih.gov/pubmed/23693018
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-248
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge